Vis enkel innførsel

dc.contributor.authorNieder, Carsten
dc.contributor.authorRessheim, Joakim Grønning
dc.contributor.authorHaukland, Ellinor Christin
dc.contributor.authorMannsåker, Bård
dc.date.accessioned2023-03-10T12:26:23Z
dc.date.available2023-03-10T12:26:23Z
dc.date.issued2022-01-29
dc.description.abstractBackground/Aim: The aim of this study was to analyze the toxicity of locoregional adjuvant breast cancer radiotherapy after implementation of this service in a rural healthcare region with long travel distance. Patients and Methods: This was a retrospective single-institution analysis of 87 consecutive female patients (the initial cohort), managed with conventionally fractionated 3-D conformal radiotherapy with or without boost, including both post mastectomy and breast conservation scenarios. Treatment was administered in line with comprehensive national guidelines. Intensity-modulated techniques were not utilized. Results: The median follow-up time was 4 years. None of the patients developed any grade IV side-effects. According to Radiation Therapy Oncology Group criteria, acute grade 2b or 3 skin toxicity was observed in 16%. In addition, 35% developed acute grade 2a skin reactions. A trend was observed regarding grade 2-3 skin toxicities and administration of a boost (p=0.058). There was a significant association between the clinical target volume of the breast and grade 2-3 skin reactions in women who had breast-conserving surgery (p=0.016). Five patients (6%) developed grade 1 pneumonitis, unrelated to dosimetric or other baseline parameters. Conclusion: The toxicity profile after a median follow-up of 4 years was in accordance with published data. Recently, intensity-modulated techniques have been implemented at the study center, which may reduce radiotherapy toxicity in patients with large clinical target volume due to better dose homogeneity.en_US
dc.identifier.citationNieder, Ressheim, Haukland, Mannsåker. Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort. Anticancer Research. 2022;42(2):923-928en_US
dc.identifier.cristinIDFRIDAID 2025715
dc.identifier.doi10.21873/anticanres.15551
dc.identifier.issn0250-7005
dc.identifier.issn1791-7530
dc.identifier.urihttps://hdl.handle.net/10037/28713
dc.language.isoengen_US
dc.publisherInternational Institute of Anticancer Researchen_US
dc.relation.journalAnticancer Research
dc.relation.projectIDSHARE - Centre for Resilience in Healthcare: 5091en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleImplementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohorten_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)